Company Overview
| Stock Name | Kindstar Global |
|---|---|
| Stock Code | 09960 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的獨立臨床特檢服務提供商,擁有最大的特檢組合,提供逾3,500種檢驗項目,涵蓋血液學、遺傳病及罕見病、傳染病、腫瘤、神經學及婦科相關疾病等專科領域,為醫院及患者提供臨床檢驗服務,並為合約研究機構、製藥公司及研究機構提供檢測服務。 |
| Listing Date | 2021-07-16 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號光谷生物城生物創新園D2-1 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.kindstar.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 9.78 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 4,890 |
| Par Value | To be extracted |
| Offer Period | 2021-06-29 to 2021-07-07 |
| Global Offering Shares | 226,405,000 shares |
| HK Public Offer Shares (Initial) | 22,640,500 shares (10.0%) |
| Public Offer Lots (Initial) | 45,281lots (Pool A22,640lots,Pool B22,641lots) |
| International Placing Shares (Initial) | 203,764,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 905,619,120 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,214,240,900 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 4,890 |
| 2 lots | 1,000 | HK$ 9,780 |
| 3 lots | 1,500 | HK$ 14,670 |
| 4 lots | 2,000 | HK$ 19,560 |
| 5 lots | 2,500 | HK$ 24,450 |
| 6 lots | 3,000 | HK$ 29,340 |
| 7 lots | 3,500 | HK$ 34,230 |
| 8 lots | 4,000 | HK$ 39,120 |
| 9 lots | 4,500 | HK$ 44,010 |
| 10 lots | 5,000 | HK$ 48,900 |
| 12 lots | 6,000 | HK$ 58,680 |
| 14 lots | 7,000 | HK$ 68,460 |
| 16 lots | 8,000 | HK$ 78,240 |
| 18 lots | 9,000 | HK$ 88,020 |
| 20 lots | 10,000 | HK$ 97,800 |
| 30 lots | 15,000 | HK$ 146,700 |
| 40 lots | 20,000 | HK$ 195,600 |
| 50 lots | 25,000 | HK$ 244,500 |
| 60 lots | 30,000 | HK$ 293,400 |
| 70 lots | 35,000 | HK$ 342,300 |
| 80 lots | 40,000 | HK$ 391,200 |
| 90 lots | 45,000 | HK$ 440,100 |
| 100 lots | 50,000 | HK$ 489,000 |
| 120 lots | 60,000 | HK$ 586,800 |
| 140 lots | 70,000 | HK$ 684,600 |
| 160 lots | 80,000 | HK$ 782,400 |
| 180 lots | 90,000 | HK$ 880,200 |
| 200 lots | 100,000 | HK$ 978,000 |
| 400 lots | 200,000 | HK$ 1,956,000 |
| 600 lots | 300,000 | HK$ 2,934,000 |
| 800 lots | 400,000 | HK$ 3,912,000 |
| 1,000 lots | 500,000 | HK$ 4,890,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,200 lots | 600,000 | HK$ 5,868,000 |
| 1,400 lots | 700,000 | HK$ 6,846,000 |
| 1,600 lots | 800,000 | HK$ 7,824,000 |
| 1,800 lots | 900,000 | HK$ 8,802,000 |
| 2,000 lots | 1,000,000 | HK$ 9,780,000 |
| 4,000 lots | 2,000,000 | HK$ 19,560,000 |
| 6,000 lots | 3,000,000 | HK$ 29,340,000 |
| 8,000 lots | 4,000,000 | HK$ 39,120,000 |
| 10,000 lots | 5,000,000 | HK$ 48,900,000 |
| 12,000 lots | 6,000,000 | HK$ 58,680,000 |
| 14,000 lots | 7,000,000 | HK$ 68,460,000 |
| 16,000 lots | 8,000,000 | HK$ 78,240,000 |
| 18,000 lots | 9,000,000 | HK$ 88,020,000 |
| 20,000 lots | 10,000,000 | HK$ 97,800,000 |
| 22,640 lots | 11,320,000 | HK$ 110,709,600 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.06B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +818% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,856,954,993 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣970.1百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 706,202 | 832,791 | 891,391 |
| Cost of sales | -327,806 | -380,577 | -430,410 |
| Gross profit | 378,396 | 452,214 | 460,981 |
| Other income and gains, net | 13,829 | 16,870 | 39,598 |
| Selling and distribution expenses | -249,528 | -274,599 | -248,521 |
| Administrative expenses | -41,890 | -48,734 | -52,320 |
| Net finance costs | -4,189 | -3,536 | -2,327 |
| Profit before tax | -59,415 | -168,605 | -962,352 |
| Income tax expense | 5,066 | -977 | -7,768 |
| Profit for the year | -54,349 | -169,582 | -970,120 |
| Profit attributable to owners | -52,674 | -169,788 | -974,020 |
Balance Sheet
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Cash and cash equivalents | 26,620 | 59,510 | 841,227 |
| Trade and bills receivables | 201,303 | 237,790 | 310,385 |
| Inventories | 31,041 | 41,173 | 44,977 |
| Total current assets | 313,678 | 446,127 | 1,355,235 |
| Total assets | 576,537 | 664,423 | 1,576,959 |
| Total current liabilities | 1,153,861 | 1,434,900 | 530,661 |
| Total liabilities | 1,194,461 | 1,463,844 | 3,411,374 |
| Total equity | -617,924 | -799,421 | -1,834,415 |
| Equity attributable to owners | -622,102 | -804,125 | -1,843,802 |
| Interest-bearing borrowings | 0 | 0 | 40,000 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Net cash from operating activities | 53,895 | 99,448 | 73,462 |
| Net cash from investing activities | -73,708 | -47,547 | -121,960 |
| Net cash from financing activities | -3,081 | -18,902 | 851,925 |
| Net increase in cash | -22,894 | 32,999 | 803,427 |
| Depreciation of PP&E | 22,505 | 26,147 | 34,471 |
| Depreciation of right-of-use assets | 14,484 | 15,432 | 15,243 |
| Amortisation of intangible assets | 783 | 1,023 | 1,081 |
| Purchase of PP&E | -58,260 | -38,351 | -23,200 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 9.04 |
|---|---|
| First Day Open | HK$ 9.78 |
| First Day Change | -7.57% |
| First Day Volume | 97344700.0 |
| First Day Turnover | 905213000.0 |
| Use of Proceeds | 1、約35%或718.8百萬港元將分配至銷售及營銷我們現有的特檢服務線以涵蓋更多醫院,尤其是三級醫院;
2、約20%或410.7百萬港元將分配至現有特檢服務線的研發,以采用創新檢測技術及持續擴大我們的檢測服務組合;
3、約15%或308.0百萬港元將分配至新特檢服務線的開發及商業化以進一步擴大我們的服務范圍;
4、約5%或102.7百萬港元將分配至撥資收購與我們的現有業務產生互補及協同效應的具吸引力的技術或檢測相關公司;
5、約10%或205.4百萬港元將分配至加強我們的檢測能力,包括擴充及升級我們的檢測設施、檢測設備及儀器以及招聘額外檢測及診斷技術人員;
6、約5%或102.7百萬港元將分配至向海外擴張至中國以外的市場,旨在滿足東南亞及中東發展中國家的未滿足醫療需求;
7、約10%或205.4百萬港元預期將用作營運資金及其他一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 77,623,860 HKD | — | 3.51% | — | 6 months | 2022-01-16 |
| 2 | BlackRock Funds | 310,510,110 HKD | — | 14.02% | — | 6 months | 2022-01-16 |
| 3 | Carmignac Funds | 116,440,680 HKD | — | 5.26% | — | 6 months | 2022-01-16 |
| 4 | CPE Funds | 271,693,290 HKD | — | 12.27% | — | 6 months | 2022-01-16 |
| 5 | DNCA Finance | 116,440,680 HKD | — | 5.26% | — | 6 months | 2022-01-16 |
| 6 | Snow Lake China Master Fund, Ltd. | 155,252,610 HKD | — | 7.01% | — | 6 months | 2022-01-16 |
| 7 | 常春藤资产管理(香港)有限公司 | 38,811,930 HKD | — | 1.75% | — | 6 months | 2022-01-16 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 黃士昂 | — |
| Company Secretary | 柴海節、陳蕙玲 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 黃醫生持股16.05%,Huang Bo先生持股10.96%,黃瑞瑨先生持股10.37%,HCA Investments持股10.06%,寧波瑞伏持股8.01%,CK Lab Tech持股8.87%等(假設超額配股權未獲行使)。 |
|---|




